Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways

[1]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[2]  T. Hung,et al.  Alpha-Mangostin Reverses Multidrug Resistance by Attenuating the Function of the Multidrug Resistance-Linked ABCG2 Transporter. , 2017, Molecular pharmaceutics.

[3]  Jian Zhang,et al.  Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway , 2016, PloS one.

[4]  Y. Lao,et al.  Nujiangexathone A, a novel compound from Garcinia nujiangensis, suppresses cervical cancer growth by targeting hnRNPK. , 2016, Cancer letters.

[5]  Jianling Xie,et al.  Guttiferone K suppresses cell motility and metastasis of hepatocellular carcinoma by restoring aberrantly reduced profilin 1 , 2016, Oncotarget.

[6]  Hyun-won Kim,et al.  Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer , 2016, Oncotarget.

[7]  Y. Lao,et al.  Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation , 2016, Cell Death and Disease.

[8]  L. Marín-Gómez,et al.  Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src , 2016, Oncotarget.

[9]  H. Duan,et al.  Inhibition of c-Src/p38 MAPK pathway ameliorates renal tubular epithelial cells apoptosis in db/db mice , 2015, Molecular and Cellular Endocrinology.

[10]  Menghong Sun,et al.  MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine , 2015, Oncotarget.

[11]  B. Goh,et al.  Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers , 2015, Oncotarget.

[12]  Yaou Zhang,et al.  DNA damage and ER stress contribute to oblongifolin C-induced cell killing in Bax/Bak-deficient cells. , 2015, Biochemical and biophysical research communications.

[13]  Wei Xu,et al.  The natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation , 2014, Autophagy.

[14]  J. Siegfried,et al.  c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met , 2012, Clinical Cancer Research.

[15]  Shuwu Xie,et al.  Gestrinone inhibits growth of human uterine leiomyoma may relate to activity regulation of ERα, Src and P38 MAPK. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[16]  T. Yu,et al.  A new anticancer compound, Oblongifolin C, inhibits tumor growth and promotes apoptosis in HeLa cells through bax activation , 2012, International Journal of Cancer.

[17]  J. Montero,et al.  Inhibition of Src Family Kinases and Receptor Tyrosine Kinases by Dasatinib: Possible Combinations in Solid Tumors , 2011, Clinical Cancer Research.

[18]  M. Guba,et al.  Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling , 2008, Oncogene.

[19]  Mahitosh Mandal,et al.  Epithelial to mesenchymal transition in head and neck squamous carcinoma , 2008, Cancer.

[20]  S. Kopetz,et al.  Src Continues Aging: Current and Future Clinical Directions , 2007, Clinical Cancer Research.

[21]  H. Burris,et al.  A phase I study (CA180021-Segment 2) of dasatinib in patients (pts) with advanced solid tumors , 2007 .

[22]  S. Kopetz.  Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. , 2007, Gastrointestinal cancer research : GCR.

[23]  K. Jauch,et al.  Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer? , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[24]  Christopher C Taylor,et al.  SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. , 2005, Cancer research.

[25]  S. Ashley,et al.  siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity. , 2004, Journal of the American College of Surgeons.

[26]  S. Ashley,et al.  Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma Cells , 2004, Clinical Cancer Research.

[27]  Christopher C. Taylor,et al.  Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line. , 2003, Biochemical and biophysical research communications.

[28]  H. Yoshiji,et al.  pp60c-src activation in lung adenocarcinoma. , 2003, European journal of cancer.

[29]  Peter F Thall,et al.  Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. , 2003, Gynecologic oncology.

[30]  Heike Allgayer,et al.  Activation of Src kinase in primary colorectal carcinoma , 2002, Cancer.

[31]  Santhosh K. P. Kumar,et al.  Ubiquitin-mediated degradation of active Src tyrosine kinase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Y. Hakak,et al.  Ubiquitin-dependent degradation of active Src , 1999, Current Biology.

[33]  H. Friess,et al.  Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. , 1998, Biochemical and biophysical research communications.